Key Takeaways:
Morgan Stanley lowered its price target for Weigao Group Co. (01066.HK) by 13.3% to HKD 5.2 from HKD 6.0, citing sustained margin pressure from China’s government-led procurement policies that have squeezed profitability across the medical technology sector.
The bank maintained its Equalweight rating on the stock but cut earnings per share forecasts for 2026, 2027, and 2028 by 14.7%, 13.8%, and 14.2%, respectively. The downgrade comes despite Morgan Stanley raising its revenue forecasts for Weigao by 4% for each of those years, reflecting a view that higher sales volumes will not offset lower prices.
The following table details the changes in Morgan Stanley's rating and price target for Weigao Group. The current stock price was not disclosed in the report.
The price target reduction highlights the persistent headwinds facing medical device makers in China. The country’s volume-based procurement (VBP) program, designed to lower healthcare costs, has led to significant price cuts for consumables and devices, directly impacting company margins even as it drives sales volume.
Weigao Group is not alone in facing these challenges. The VBP policy has become a key risk factor for both domestic and international medical technology firms operating in China. In its recent earnings report, Fresenius Medical Care (NYSE: FMS) noted that its Care Enablement business was hurt by "negative impacts from volume-based procurement and stricter tender requirements in China."
Similarly, life sciences company Revvity Inc. (NYSE: RVTY) has described China as a "drag due to volume-based procurement and pricing pressures" affecting its diagnostics segment. Market analysis shows the impact can be severe, with prices for certain research-use-only lab kits falling by as much as 30% in recent years due to intense local competition fueled by VBP tenders.
The downgrade from Morgan Stanley suggests that even with a diversified portfolio spanning consumables, orthopedics, and blood management, Weigao cannot escape the broad pricing reset in the Chinese healthcare market. The key question for investors is whether efficiency gains and new product launches can stabilize margins against the ongoing policy-driven price erosion.
This article is for informational purposes only and does not constitute investment advice.
